Skip to main content
. Author manuscript; available in PMC: 2010 Jul 6.
Published in final edited form as: J Neurosci. 2010 Jan 6;30(1):38. doi: 10.1523/JNEUROSCI.4346-09.2010

Figure 6. Immunohistochemical staining of pCaMKIIα expression after the treatment with KN93.

Figure 6

Morphine or saline treated mice were administered (i.t.) with KN93 (15–45nmol), KN92 (45nmol), or saline on day 5. Mice were sacrificed 1h after the treatment with saline or KN93 (45nmol, i.t.). The lumber spinal section was dissected out and immunostained with pCaMKIIα antibody. Quantitative analysis of pCaMKIIα immunoreactivity was performed by counting the number of positively stained cells using the MetaMorph Imaging Software. No pCaMKIIα immunoreactivity was detected if the 1st antibody was omitted (D) or if the 1st antibody was incubated in the presence of pCaMKIIαT286 blocking peptide (Santa Cruz Biotechnology). Data are expressed in Mean ± SEM. †††, p<0.001, compared with the morphine treated group; n=3 for each group. Scale bars are 200μm (A-1; B-1; C-1; D; E), 100μm (A-2; B-2; C-2), or 20μm (A-3; B-3; C-3).